| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DCLK2 |
| Uniprot No | Q8N568 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-766aa |
| 氨基酸序列 | MASTRSIELE HFEERDKRPR PGSRRGAPSS SGGSSSSGPK GNGLIPSPAH SAHCSFYRTR TLQALSSEKK AKKARFYRNG DRYFKGLVFA ISSDRFRSFD ALLIELTRSL SDNVNLPQGV RTIYTIDGSR KVTSLDELLE GESYVCASNE PFRKVDYTKN INPNWSVNIK GGTSRALAAA SSVKSEVKES KDFIKPKLVT VIRSGVKPRK AVRILLNKKT AHSFEQVLTD ITEAIKLDSG VVKRLCTLDG KQVTCLQDFF GDDDVFIACG PEKFRYAQDD FVLDHSECRV LKSSYSRSSA VKYSGSKSPG PSRRSKSPAS VNGTPSSQLS TPKSTKSSSS SPTSPGSFRG LKQISAHGRS SSNVNGGPEL DRCISPEGVN GNRCSESSTL LEKYKIGKVI GDGNFAVVKE CIDRSTGKEF ALKIIDKAKC CGKEHLIENE VSILRRVKHP NIIMLVEEME TATELFLVME LVKGGDLFDA ITSSTKYTER DGSAMVYNLA NALRYLHGLS IVHRDIKPEN LLVCEYPDGT KSLKLGDFGL ATVVEGPLYT VCGTPTYVAP EIIAETGYGL KVDIWAAGVI TYILLCGFPP FRSENNLQED LFDQILAGKL EFPAPYWDNI TDSAKELISQ MLQVNVEARC TAGQILSHPW VSDDASQENN MQAEVTGKLK QHFNNALPKQ NSTTTGVSVI MNTALDKEGQ IFCSKHCQDS GRPGMEPISP VPPSVEEIPV PGEAVPAPTP PESPTPHPPP AAPGGERAGT WRRHRD |
| 预测分子量 | 83,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DCLK2重组蛋白的虚构参考文献示例(仅供格式参考，实际文献需查询数据库)：
1. **文献名称**：*Structural and Functional Analysis of DCLK2 Recombinant Protein in Kinase Signaling*
**作者**：Smith A, et al.
**摘要**：本研究通过大肠杆菌表达系统成功纯化DCLK2重组蛋白，并解析其激酶结构域的三维结构。实验表明，DCLK2在体外表现出对微管结合蛋白的磷酸化活性，提示其在细胞周期调控中的作用。
2. **文献名称**：*DCLK2 Recombinant Protein Modulates Cancer Stem Cell Properties in Colorectal Cancer*
**作者**：Lee J, et al.
**摘要**：利用哺乳动物细胞表达的重组DCLK2蛋白，研究发现其过表达可增强结直肠癌细胞的自我更新能力和化疗耐药性，表明DCLK2可能作为肿瘤干细胞标志物及治疗靶点。
3. **文献名称**：*Development of a DCLK2-Specific Inhibitor Using Recombinant Protein Screening*
**作者**：Wang Y, et al.
**摘要**：通过高通量筛选与DCLK2重组蛋白结合的化合物，鉴定出新型小分子抑制剂，可显著抑制胰腺癌细胞迁移，为靶向DCLK2的抗癌药物开发提供依据。
4. **文献名称**：*Comparative Study of DCLK1 and DCLK2 Recombinant Proteins in Neuronal Development*
**作者**：Garcia R, et al.
**摘要**：对比分析DCLK1和DCLK2重组蛋白的功能差异，发现DCLK2在神经元轴突导向中具有独特作用，其激酶活性依赖钙调蛋白结合域。
---
**注意**：以上内容为模拟生成，实际文献请通过PubMed、Google Scholar等平台检索关键词“DCLK2 recombinant protein”获取。
**Background of DCLK2 Recombinant Protein**
DCLK2 (Doublecortin-like kinase 2) is a member of the doublecortin (DCX) protein family, characterized by dual N-terminal DCX domains that bind microtubules and a C-terminal serine/threonine kinase domain. It plays critical roles in regulating microtubule dynamics, neuronal development, and cellular migration. Unlike its paralog DCLK1. which is extensively studied in neurogenesis and cancer, DCLK2 remains less understood but shares structural and functional similarities, including involvement in cytoskeletal organization and signal transduction pathways.
Recombinant DCLK2 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional protein for research. This allows precise study of its kinase activity, microtubule-binding properties, and interactions with partners like MAPs (microtubule-associated proteins) or components of the PI3K/AKT/mTOR pathway. Researchers utilize DCLK2 recombinant protein to investigate its role in diseases, particularly cancer, where aberrant expression correlates with tumor progression, metastasis, and therapy resistance. It is also implicated in neurodevelopmental disorders and neurodegenerative conditions, possibly due to disrupted microtubule stability.
Recent studies highlight DCLK2’s splice variants and post-translational modifications, which may diversify its functions. Its recombinant forms, often tagged for detection (e.g., His, GFP), enable *in vitro* assays, structural studies, and drug screening. Targeting DCLK2 kinase activity has emerged as a therapeutic strategy, driving demand for high-purity recombinant protein to validate inhibitors or antibodies. Ongoing research aims to clarify its tissue-specific roles and potential as a biomarker or therapeutic target in precision medicine.
×
